OPKNasdaqPharmaceutical PreparationsFiscal year ends December 31
OPKO HEALTH, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q/A on Aug 28, 2026
$1.61+0.08 (+5.23%)
Close on Oct 19, 2026
- Market cap
- $1.22B
- P/E (TTM)
- –
- Dividend yield
- –
OPKO HEALTH, INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics [Member] | – | – | – | – | – | – | – | – | $889.08M | $1.01B | – | – |
| Pharmaceutical [Member] | – | – | – | – | – | – | – | – | $107.76M | $83.47M | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics [Member] | $21.26M | -$24.13M | -$155.60M | -$173.65M | $98.07M | $138.92M | -$123.36M | -$44.94M | -$136.54M | -$3.39M | -188.1% |
| Pharmaceutical [Member] | -$98.34M | -$86.80M | $41.18M | -$12.96M | -$19.05M | -$43.52M | -$109.06M | -$82.64M | -$84.29M | -$33.12M | +13.3% |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Service [Member] | $370.28M | $480.67M | $515.28M | $755.63M | $1.61B | $1.26B | $716.43M | $813.25M | $782.71M | $928.57M | 61.0% | -23.0% |
| Product [Member] | $156.92M | $155.11M | $167.56M | $142.85M | $141.77M | $119.95M | $112.18M | $107.11M | $107.76M | $83.47M | 25.9% | +1.2% |
| Transfer of Intellectual Property and Other [Member] | $79.68M | $77.36M | $180.66M | $105.72M | $25.84M | $53.22M | $73.32M | $69.90M | $75.50M | $105.46M | 13.1% | +3.0% |
| Rayaldee [Member] | $59.39M | $69.30M | $67.55M | $59.56M | $64.30M | $88.19M | $73.97M | $36.72M | $9.10M | $0 | 9.8% | -14.3% |
| Client payers | – | – | – | $316.31M | $843.41M | $637.65M | $158.53M | $148.07M | $126.26M | $127.36M | – | – |
| Government payers | – | – | – | $97.19M | $222.24M | $90.29M | $115.71M | $150.85M | $140.20M | $118.53M | – | – |
| Healthcare insurers | – | – | – | $326.14M | $520.24M | $483.64M | $421.39M | $493.00M | $495.21M | $649.04M | – | – |
| Patients | – | – | – | $15.99M | $21.22M | $50.67M | $20.81M | $21.33M | $21.04M | $33.65M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $436.06M | $546.30M | $597.82M | $783.21M | $1.64B | $1.32B | $751.10M | $837.51M | $803.85M | $933.50M | 71.9% | -20.2% |
| Chile | $62.38M | $65.05M | $68.49M | $62.04M | $63.80M | $44.15M | $33.64M | $41.22M | $44.29M | $35.36M | 10.3% | -4.1% |
| Ireland | $51.40M | $48.40M | $141.47M | $117.21M | $32.81M | $43.92M | $81.17M | $78.10M | $80.91M | $114.51M | 8.5% | +6.2% |
| Spain | $26.73M | $24.63M | $23.52M | $22.48M | $22.68M | $16.93M | $18.75M | $18.20M | $18.29M | $15.81M | 4.4% | +8.5% |
| Mexico | $25.52M | $23.87M | $20.22M | $14.55M | $11.01M | $7.87M | $8.03M | $5.60M | $4.61M | $2.99M | 4.2% | +6.9% |
| Other Countries [Member] | $4.27M | $3.12M | $2.25M | $863.00K | $507.00K | $526.00K | $476.00K | $167.00K | $121.00K | $6.00K | 0.7% | +36.8% |
| Israel | $522.00K | $1.77M | $9.74M | $3.85M | $3.56M | $4.25M | $8.77M | $9.48M | $13.95M | $15.32M | 0.1% | -70.5% |
From the segment and revenue-disaggregation notes of Opko Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.